Payment overview · 2025
General Payments
$924.78
42 reported records · 16 companies
Healthcare provider profile · identity verified
John Timothy Cope, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DEMOREST, GA · NPI 1609878974
Verified facts
What the public records show
CMS Open Payments records show John Timothy Cope, M.D. received $924.78 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $376.99 | 40.8% | 15 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$99.51 | 10.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.63 | 6.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.23 | 5.0% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.84 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.93 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.09 | 4.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.62 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.47 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.41 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.32 | 2.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.51 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.73 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.12 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.33 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.05 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $924.78 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $297.25 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $145.12 | 7 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $99.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.74 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.63 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.23 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 216 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 122 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
216 | 216 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
43 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 757 | 213 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 159 |
| Omeprazole | Omeprazole | 557 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 144 |
| Losartan Potassium | Losartan Potassium | 500 | 141 |
| Alprazolam | Alprazolam | 389 | 76 |
| Lisinopril | Lisinopril | 363 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 87 |
| Metformin Hcl | Metformin Hcl | 347 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 82 |
| Tramadol Hcl | Tramadol Hcl | 301 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 80 |
| Gabapentin | Gabapentin | 273 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 62 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 216 | 216 |
| Eliquis | Apixaban | 205 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 46 |
| Simvastatin | Simvastatin | 188 | 50 |
| Potassium Chloride | Potassium Chloride | 185 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 52 |
| Montelukast Sodium | Montelukast Sodium | 174 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 170 | 40 |
| Sertraline Hcl | Sertraline Hcl | 169 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 43 |
| Lorazepam | Lorazepam | 154 | 31 |
| Meloxicam | Meloxicam | 153 | 50 |
| Allopurinol | Allopurinol | 148 | 43 |
| Furosemide | Furosemide | 143 | 42 |
| Trazodone Hcl | Trazodone Hcl | 139 | 30 |
| Carvedilol | Carvedilol | 135 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 47 |
| Farxiga | Dapagliflozin Propanediol | 122 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 25 |
| Ozempic | Semaglutide | 117 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 28 |
| Mounjaro | Tirzepatide | 115 | 26 |
| Synthroid | Levothyroxine Sodium | 106 | 23 |
| Glimepiride | Glimepiride | 104 | 28 |
| Ezetimibe | Ezetimibe | 102 | 34 |
| Metformin Hcl Er | Metformin Hcl | 91 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 21 |
| Xarelto | Rivaroxaban | 82 | 16 |
| Famotidine | Famotidine | 81 | 24 |
| Donepezil Hcl | Donepezil Hcl | 80 | 24 |
| Finasteride | Finasteride | 80 | 22 |
| Atenolol | Atenolol | 78 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 21 |
| Jardiance | Empagliflozin | 74 | 18 |
| Benazepril Hcl | Benazepril Hcl | 73 | 19 |
| Glipizide | Glipizide | 73 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 19 |
| Diazepam | Diazepam | 71 | 17 |
| Temazepam | Temazepam | 71 | 12 |
| Lansoprazole | Lansoprazole | 66 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 17 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 63 | 63 |
| Azithromycin | Azithromycin | 61 | 48 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 59 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 57 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | 14 |
| Spironolactone | Spironolactone | 54 | 14 |
| Fenofibrate | Fenofibrate,micronized | 53 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 53 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 13 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 15 |
| Glipizide Er | Glipizide | 51 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Prednisone | Prednisone | 45 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 43 | 34 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Ondansetron Odt | Ondansetron | 37 | 14 |
| Acyclovir | Acyclovir | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Fluconazole | Fluconazole | 34 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 17 |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 18 |
| Pregabalin | Pregabalin | 32 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Estradiol | Estradiol | 28 | 11 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 22 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Prolia | Denosumab | 19 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Ramipril | Ramipril | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $924.78 · 42 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INSPIRE, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, Korlym, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, VOQUEZNA, Wegovy, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error